Tanespimycin is a water-soluble benzoquinone antineoplastic antibiotic. It acts as an inhibitor of Hsp90, a heat shock protein that plays a central role in promoting the functionality and stability of a group of proteins associated with cancer. Tanespimycin is a derivative of geldanamycin, an antibiotic that is being studied in the treatment of cancer and patients with certain types of leukemia or solid tumors, especially kidney tumors.
Intratec offers professional, easy-to-understand reports examining Tanespimycin production. Each study describes an industrial plant, including main process units and site infrastructure, and presents an independent analysis of capital and operating costs. All reports are based on the most recent economic data available (Q2 2019).
You can find below reports focused on Tanespimycin production processes currently offered by Intratec. If none of the off-the-shelf reports listed below fits your needs, you can request a bespoke report tailored to your needs, for as low as USD 2,900!